 Incyte Corp. INCY, -1.46 said Monday that the Food and Drug Administration approved Opzelura as a topical repigmentation treatment for patients with nonsegmental vitiligo. Vitiligo is an autoimmune disease that can cause patients to lose color in patches on their hair and skin. 